Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Intervirology

• Publication date

  2010-01-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000274975PMID 20068348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnosis, management, and treatment of hepatitis C: An update

  2009cited by this paper
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  2009influential reference
• 990 PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN VERSUS PEGINTERFERON ALPHA-2B PLUS RIBAVIRIN IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS OF A PROSPECTIVE RANDOMISED TRIAL

  2008influential reference
• New hepatitis C guidelines for the Asia–Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection

  2007cited by this paper
• A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

  2006cited by this paper
• Pegylated interferons: chemical and clinical differences

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

  2003influential reference
• Viral hepatitis C.

  2003cited by this paper
• Viral Dynamics and Pharmacokinetics of Peginterferon Alpha-2A and Peginterferon Alpha-2B in Naive Patients with Chronic Hepatitis C: A Randomized, Controlled Study

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Hepatitis C virus infection.

  2001cited by this paper
• Pegylation: a novel process for modifying pharmacokinetics.

  2001cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS

  2000cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C

  2000cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-γ as a Novel Antiviral Approach Against COVID-19

  2020cites this paper
• Antiviral Polymers: Past Approaches and Future Possibilities

  2020cites this paper
• Cost‐effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea

  2018cites this paper
• 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

  2018cites this paper
• Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

  2018cites this paper
• KASL clinical practice guidelines: management of hepatitis C

  2016cites this paper
• Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.

  2014cites this paper
• KASL clinical practice guidelines: Management of Hepatitis C

  2014cites this paper
• Pegylated Interferon-a2a and Ribavirin versus Pegylated Interferon-a2b and Ribavirin in Chronic Hepatitis C

  2013cites this paper
• Evaluation of 219 Patients with Chronic Hepatitis C Receiving Pegylated Interferon + Ribavirin Treatment

  2013cites this paper
• Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area

  2013cites this paper
• Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C

  2013cites this paper
• Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

  2013cites this paper
• Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

  2012influential citation
• Peginterferon α‐2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single‐centre study of 367 cases

  2010cites this paper
• A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

  2010cites this paper
• The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis

  2010cites this paper